Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 14;22(4):36.
doi: 10.1007/s11912-020-0893-0.

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived

Kate Milne  1   2 , Beattie Sturrock  3   4 , Timothy Chevassut  3   4
Affiliations
Review

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived

Kate Milne et al. Curr Oncol Rep. .

Abstract

Purpose of review: Chronic lymphocytic leukaemia is now recognised as a heterogenous disease with a variety of clinical outcomes. Here we summarise the way it is currently stratified according to genetic risk and patient characteristics and the treatment approaches used for these different subgroups.

Recent findings: Certain patients appear to sustain MRD negativity after combination chemoimmunotherapy, leading to the suggestion that their CLL may be cured. However, 17p-deleted, p53-mutated or IGHV-UM subgroups are generally resistant to FCR, and much better responses are seen with ibrutinib and venetoclax, frequently inducing MRD negativity that hopefully will be translated into durable remissions. Small molecule inhibitors have already revolutionised CLL treatment. Going forward, we anticipate their use in the majority of patients, early after diagnosis and with curative intent.

Keywords: Chemoimmunotherapy; Chronic lymphocytic leukaemia; Future; Ibrutinib; Venetoclax.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow chart showing the decision process and treatment options in management of previously untreated CLL that meets the iwCLL criteria for treatment and in relapsed or refractory disease
See this image and copyright information in PMC

References

    1. Chronic lymphocytic leukemia - Cancer Stat Facts [Internet]. [cited 2019 Nov 17]. Available from: https://seer.cancer.gov/statfacts/html/clyl.html.
    1. Chronic lymphocytic leukaemia (CLL) statistics | Cancer Research UK [Internet]. [cited 2019 Nov 17]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s....
    1. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–1517. doi: 10.3324/haematol.2018.193615. - DOI - PMC - PubMed
    1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916. doi: 10.1056/NEJM200012283432602. - DOI - PubMed
    1. Rai KR, Kipps TJ, Kay NE, Van Dyke D. NIH Public Access. 2011;203(2):134–140.

Publication types

MeSH terms